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CRCp-21-Activated kinase 1 (PAK1) enhances colorectal cancer (CRC) progression by stimulating Wnt/β-catenin,
ERK and AKT pathways. PAK1 also promotes CRC survival via up-regulation of hypoxia-inducible factor 1α
(HIF-1α), a key player in cancer survival. Glaucarubinone, a quassinoid natural product, inhibits pancreatic
cancer growth by down-regulation of PAK1. The aim of this study was to investigate the effect of glaucarubinone
on CRC growth and metastasis, and the mechanism involved. Cell proliferation was measured in vitro by [3H]-
thymidine incorporation and in vivo by volume of tumor xenografts. Protein concentrations were measured by
Western blotting of cell extracts. We report here that glaucarubinone inhibited CRC growth both in vitro and
in vivo. The potency of glaucarubinone as an inhibitor of cell proliferation was negatively correlated to PAK1
expression in CRC cells. Glaucarubinone suppressed the expression of HIF-1α and β-catenin. Knockdown of
PAK1 by shRNA enhanced inhibition by glaucarubinone while constitutively active PAK1 blocked the inhibitory
effect. Our ﬁndings indicate that glaucarubinone inhibited CRC growth by down-regulation of HIF-1α and β-
catenin via a PAK1-dependent pathway.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Colorectal cancer (CRC) develops through multiple steps involving
alterations in cell proliferation, differentiation, survival and cell death.
Mutations in the components of the Wnt/β-catenin signal pathway
such as the adenomatous polyposis coli (Apc) tumor suppressor gene
and the β-catenin (CTNNB1) oncogene occur in over 90% of CRCs,
trigger adenomatous polyp formation, and initiate colorectal neoplasia
[1]. Loss-of-functionmutations of Apc occur inmore than 60% of colonic
adenomas and carcinomas [2], and cause cytoplasmic accumulation and
nuclear translocation of β-catenin leading to constitutive activation of
Wnt signaling.
The hypoxia associated with tumor expansion initiates a number of
oncogenic responses. Hypoxia suppresses proliferation, initiates angio-
genesis and cell migration, and drives the progression to malignant
tumor phenotypes [3]. Hypoxia-inducible factor-1α (HIF-1α) plays a
central role in the hypoxia-driven changes in tumor phenotype and itsRC, colorectal cancer; Glau,
c, adenomatous polyposis coli
niversity of Melbourne, Austin
l.: +61 3 9496 5593; fax: +61expression is often associatedwith poor prognosis [4–6].While the aber-
rant activation ofβ-catenin promotes cell proliferation and initiates colo-
rectal tumorigenesis through β-catenin/TCF4 signaling, the expansion of
tumors and the inadequacy of their local vasculature result in areas of
hypoxia, which in turn induce the expression of HIF-1α and stabilize
the protein. Under hypoxia, HIF-1α competes with TCF4 for binding to
β-catenin, and β-catenin switches from binding with TCF4 and promot-
ing cell proliferation to binding with HIF-1α, thereby enhancing cell
survival and adaptation to hypoxia [7]. However, the expression of HIF-
1α is not only induced under hypoxic condition. In cancer cells, growth
factors, oncogenes, or loss-of-function mutations of tumor suppressor
genes can induce HIF-1α expression under normoxic conditions [8,9].
HIF-1α stimulates normoxic growth of CRC cells and prevents premature
senescence and aging of cells, particularly followingγ-irradiation [10,11].
The p-21-activated kinase family of 6 serine/threonine kinases is
characterized by an N-terminal regulatory domain and a highly con-
served C-terminal kinase domain [12]. PAKs are upregulated and/or
hyperactivated in many human cancers including CRC [13]. The expres-
sion of PAK1 increases with progression through the adenoma to carci-
noma sequence, with the most dramatic increases in invasive and
metastatic CRC [14]. PAK1 promotes CRC growth by activation of ERK
and AKT pathways [15]. PAK1 also associates with and phosphorylates
β-catenin in CRC cells, and PAK1 knockdown inhibits β-catenin expres-
sion and suppresses the activation of the β-catenin signal pathway [16,
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both in vitro and in vivo [18]. These lines of evidence support the idea that
PAK1 acts as a point of convergencewheremultiple signals intersect, and
plays a key role in CRC progression.
The natural products, quassinoids, have been isolated from various
species of the Simaroubaceae plant family, and have a range of biologi-
cal activities including antitumor properties [19]. Quassinoids suppress
tumor growth by inhibition of protein synthesis and the AP-1 transcrip-
tion factor, induction of apoptosis, and down-regulation of the myc
oncogene [20–24]. The quassinoid 6α-tigloyloxychapparrinone inhibits
HIF-1α expression by reducing phosphorylation of eukaryotic translation
initiation factor 4E [25]. Recently we have reported that glaucarubinone,
a member of the quassinoid family suppresses pancreatic cancer growth,
synergistically with gemcitabine, by down-regulation of PAK1 and PAK4
[26]. These observations suggest that glaucarubinone may exert its anti-
tumor effect through modulation of PAK-dependent pathways. In the
current study, we have further investigated the effect of glaucarubinone
on CRC growth and metastasis/invasion and the possible mechanisms
involved.We demonstrate here that glaucarubinone inhibits CRC growth
in vitro and in vivo by suppression of HIF-1α and β-catenin via a PAK1-
dependent pathway.
2. Material and methods
2.1. Cells and transfection
The human colorectal cancer (CRC) cell lines DLD1, HCT116, HT29,
SW480 and SW1222 were obtained from the ATCC and cultured in
Dulbecco'sModiﬁed Eagle'smedium (DMEM) containing 5% fetal bovine
serum (FBS). None of these CRC cell lines have mutations in either PAK1
or PAK2; DLD1 only has a missense mutation in PAK4 [27]. The PAK1
knockdown (KD) clones of HCT116 cells were generated by transfection
with plasmid DNAs encoding either shRNA sequences (SABioscience,
Frederick, MD) to silence the PAK1 gene speciﬁcally or with a scrambled
sequence as a negative control using Lipofectin Reagent (Invitrogen,
Melbourne, Australia) as described previously [15]. The constitutively
active PAK1 constructs (generously provided by Dr. Gary Bokoch,
The Scripps Research Institute, La Jolla, CA) were sub-cloned into
the pCDNA3.1 vector (Invitrogen, Melbourne, Australia). CA PAK1 plas-
mid DNA was transfected into SW480 cells using Lipofectin Reagent
(Invitrogen) as described previously [18].
2.2. Cell proliferation assay
Cell proliferation was measured using 3H-thymidine incorporation.
Cells were seeded in a 96-well plate at 5 × 103 cells/well in DMEM con-
taining 5% FBS, with 1 μCi/well [methyl-3H]-thymidine (Perkin Elmer,
Boston,MA) in thepresence or absence of glaucarubinoneor ailanthinone
(prepared as prescribed previously [21], and obtained from the National
Cancer Institute) at the indicated concentrations. After 24 h, cells were
harvested using a NUNC cell harvester (Nunc, Roskilde, Denmark). The
amount of 3H-thymidine incorporated through DNA synthesis was
detected with a β-counter (Packard, Meriden, CT).
2.3. Cell migration assay
Cell migration was determined using the Boyden Chamber assay
described previously [15].Membranes (8 μmpore size, BectonDickinson,
NJ) were coated with 3 μg human ﬁbronectin on the lower surfaces and
placed into a 24-well plate containing 600 μl/well of serum-free DMEM
with 0.1% BSA. Cells (2–5 × 104/100 μl/chamber) were added to the
upper chambers and incubated for 24 h at 37 °C in a 5% CO2 atmosphere
plus or minus glaucarubinone or ailanthinone. The cells on the upper
surface of the membranes were removed by wiping with a cotton swab
before the membranes were ﬁxed and stained with Quick-Dip (Fronine,
Sydney, Australia). The cells that had migrated to the lower surface ofthe membranes were counted from 24 ﬁelds at 40 times magniﬁcation
using a NIKON Coolscope (Coherent Scientiﬁc, Adelaide, Australia).
2.4. PAK kinase assays
The PAK kinase assay was performed on immunoprecipitates as
described previously [28]. CRC cells were treated with glaucarubinone
(100 or 500 nM) for 24 h and lysed. The cell lysates were incubated
with anti-PAK antibody and protein A beads for 4 h at 4 °C. PAK kinase
activity in the immunoprecipitates was assayed using myelin basic
protein (MBP, 5 μg/ml) as substrate, and the phosphorylatedMBPwas vi-
sualized in a BAS-3000 phospho-imager (Berthold, Bundoora, Australia).
The ratio of phosphorylated MBP to total MBP was calculated and taken
to represent the kinase activity. The amount of PAK protein was deter-
mined by Western blots.
To generate aGST-PAK1 fusion protein, thewild type (WT) PAK1 con-
struct (generously provided by Dr. Gary Bokoch, The Scripps Research
Institute, La Jolla, CA) was sub-cloned into the pGEX-2TH vector
(Invitrogen, Melbourne, Australia). The GST-PAK1 fusion protein
was puriﬁed from bacterial cultures as described previously [29].
0.1 μg of GST-PAK1 fusion protein was incubated with 5 μg MBP in
the presence of different concentrations of glaucarubinone or the
PAK1 inhibitor Frax-597 (10 nM SYNthesis Pty. Ltd., Melbourne,
Australia) in kinase buffer (40 mM HEPES pH 7.4, 10 mM MgCl2,
20 μM ATP) containing [32P]-ATP. The reaction mixture was subjected
to 12% SDS-PAGE, and the phosphorylated MBP was visualized in a
BAS-3000 phospho-imager. The ratio of phosphorylated MBP to total
MBP was calculated and taken to represent the kinase activity.
2.5. Mouse xenograft study
This study was carried out in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals of the
Austin Health Animal Ethics Committee. The mouse experiments were
conducted at the Austin Bioresource Centre, Austin Health (Melbourne,
Australia) with ethics approval (permit number: A2010/04016) from
the Austin Health Animal Ethics Committee. SCID mice were purchased
from the Animal Resource Centre (Perth, Australia). HCT116 and DLD1
cells (2.5 × 106 cells/100 μl/site) were injected subcutaneously into the
ﬂanks of 6 week old SCID mice. When the tumor size reached 50 mm3
(day 4 after intra-peritoneal injection for HCT116 cells, day 9 for DLD1
cells), glaucarubinone was given by intra-peritoneal injection, every
day fromMonday to Friday for 3 weeks. Therewere sixmice in both con-
trol (5%DMSO in saline) and glaucarubinone-treated (1 mg/kg, dissolved
in 5% DMSO in saline) groups. Tumor dimensions were measured with a
caliper, and tumor volume calculated as 1/2 l (length) × w2 (width). At
the end of the experiment, mice were sacriﬁced. Tumors were excised,
weighed and frozen for protein extraction and Western blot.
2.6. Western blots
Cells were lysed in SDS sample buffer. The proteins in cell lysates
were resolved by SDS-polyacrylamide gel (SDS-PAGE), and detected
with antibodies against HIF-1α (BD Biosciences, San Jose, California),
PAK1 (Santa Cruz Biotechnology, Santa Cruz, CA), phospho-PAK1
(Ser144), PAK2, PAK4, β-catenin, ERK, pERK, AKT, pAKT and GAPDH
(Cell Signaling). Bound antibodies were visualized using ECL reagents
(GE Healthcare, Buckinghamshire, UK), and the density of each band
was analyzedusingMulti-gauge computer software (Berthold, Bundoora,
Australia).
50 mg samples of frozen xenograft tumors were homogenized using
an ultra Turrax T25 homogenizer (Janke and Kunkel, Staufen, Germany)
in 500 μl tissue lysis buffer (150 mM NaCl, pH 7.5, 50 mM HEPES,
10 mM EDTA, 10 mM Na4P2O7, 100 mM NaF, protease inhibitor cocktail
(Roche)) as described before [18]. The lysates were then centrifuged at
13,000 rpm for 10 min at 4 °C, and supernatants were collected. Proteins
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the antibodies indicated in the text.
2.7. Quantitative real time PCR
To measure PAK1 mRNA, cells were seeded at 4 × 105/well in 6-well
plates, and total RNA was extracted with TRIzol (Invitrogen) and con-
verted to cDNA using the Superscript™ III ﬁrst strand synthesis system
(Invitrogen). The resulting cDNA transcripts were used for real time
PCR ampliﬁcation with an ABI 7700 Sequence Detector (Applied
Biosystems, Melbourne, Australia) and Taqman chemistry according
to the manufacturer's instructions. Results were normalized to 18S
RNA expression.
2.8. Statistical analysis
All values are expressed asmeans± standard error. Results were an-
alyzed by one-way analysis of variance or t-test as appropriate with the
program Sigma Stat (Systat Software Inc., San Jose, CA). The program
Sigmaplot 12was used for regression analysis (Systat Software Inc.). Dif-
ferences between two means with p b 0.05 were considered signiﬁcant.
3. Results
3.1. Glaucarubinone suppressed CRC cell proliferation and migration
The effects of glaucarubinone and ailanthinone, a structural ana-
logue of glaucarubinone [30], on CRC cell proliferation and migration
were determined by 3H-thymidine incorporation and Boyden chamber
assay, respectively. Both glaucarubinone and ailanthinone decreasedFig. 1. Glaucarubinone and ailanthinone inhibited CRC cell proliferation andmigration. CRC cells
(A, B) and migration (C, D) were measured by 3H-thymidine incorporation (A, B) and Boyden
without any treatmentwere taken as 100%. The datawere summarized from three independent e
glaucarubinone or ailanthinone. *, p b 0.05; **, p b 0.01; ***, p b 0.001 compared to the values oCRC cell proliferation in a dose dependent manner (Fig. 1A & B). The
maximal inhibition by glaucarubinone on proliferation was achieved
at 500 nM for DLD1, HCT116 and SW480 cells, 1000 nM for SW1222
and N1000 nM for HT29 cells (Fig. 1A). The maximal inhibition by
ailanthinone on proliferation was achieved at 200 nM for DLD1, SW480
and HCT116, 300 nM for HT29 cells, and N500 nM for SW1222 cells
(Fig. 1B). Similarly both glaucarubinone and ailanthinone suppressed
themigration of DLD1 and HCT116 cells (Fig. 1C & D). Themaximal inhi-
bition of migration by glaucarubinone and ailanthinone was at
100 nM. The IC50 values for inhibition of proliferation and migration by
glaucarubinone and ailanthinone are listed in Supplementary Table 1.
These results indicated that CRC cell growth and migration/invasion
were inhibited by glaucarubinone and ailanthinone in the nM concentra-
tion range.
3.2. Inhibition of CRC cell growth by glaucarubinone correlated with PAK1
expression
To determine if there was any connection between the inhibition of
CRC cell proliferation by glaucarubinone and PAK expression, the levels
of PAK1 and PAK2 in a panel of CRC cells were measured by Western
blot. Among ﬁve CRC cell lines tested, similar levels of PAK1 were
detected in DLD1, HCT116 and SW480 cells while signiﬁcantly higher
levels of PAK1 were expressed in SW1222 and HT29 cells (Fig. 2B).
The IC50 values for the inhibition of proliferation by glaucarubinone
were similar among DLD1, HCT116 and SW480 (all around 100 nM),
while the IC50 values for glaucarubinone inhibition on SW1222 and
HT29 cells were signiﬁcantly higher, at 376 nMand 595 nMrespectively
(Fig. 2A). Regression analysis showed that the IC50 for the inhibition by
glaucarubinone of CRC cell proliferation was signiﬁcantly correlatedwere incubatedwith glaucarubinone (A, C) or ailanthinone (B, D) for 24 h. Cell proliferation
chamber assay (C, D) as described in Material and methods. The values from control cells
xperiments and presented asmean± standard error. Controls were not treatedwith either
f non-treated controls.
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(p= 0.1507, Fig. 2D). Furthermore the inhibitory effect of glaucarubinone
on proliferation was signiﬁcantly enhanced in PAK1 knockdown (KD)
HCT116 cells with 50% lower IC50 values observed in two PAK1 KD clones
(Fig. 2E). On the other hand, the inhibitory effect of glaucarubinone on
proliferation was signiﬁcantly decreased in SW480 cells that had been
transfected with a plasmid encoding a constitutively active (CA) PAK1
(Fig. 2F). The amounts of PAK1 in KD and CA cell lines are shown at the
top of Fig. 2E and F, respectively. The expression and activity of PAK1 in
KD or CA cell lines were also presented in our previous studies [16,18].
These results showed that inhibition by glaucarubinone of cell growth
correlated with PAK1 expression levels in CRC cells.
3.3. Glaucarubinone inhibited PAK1 activity by decreasing its
protein expression
To determine the effect of glaucarubinone on PAK1 activity, 4 CRC
cell lines were treated with glaucarubinone at 100 and 500 nM for
24 h. The cells were then lysed and the cell lysates were subjected to
an in vitro kinase assay using myelin basic protein (MBP) as the sub-
strate. Glaucarubinone reduced the kinase activity of PAK1 in DLD1,
HCT116 and SW480 cells, but not HT29 cells which had signiﬁcantly
higher levels of PAK1 (Fig. 3A). Similarly, glaucarubinone decreasedFig. 2.PAK1 expression correlatedwith the inhibition of CRC cell proliferation by glaucarubinone
by curve ﬁtting the results shown in Fig. 1A. The concentration of PAK1 in CRC cells was determi
PAK1 protein expression from different CRC cell lines, the PAK1/GAPDH ratio in SW480 cells, wh
values and the PAK1 (C) or PAK2 (D) concentration was calculated by regression analysis with
clone (NC8) of HCT116 cells (E) were cultured with different concentrations of glaucarubinon
(VO1) of SW480 cells (F) were also cultured with different concentrations of glaucarubinone
independent experiments.*, p b 0.05; **, p b 0.01 compared to the values of NC8 (E) or VO1 (F)the levels of the phosphorylated, active form of PAK1 in DLD1, HCT116
and SW480 cells, but not HT29 cells (Fig. 3B), and the levels of total
PAK1 in all CRC lines tested (Fig. 3C). The reduction by glaucarubinone
of PAK1 protein expression was not caused by changes in proteasomal
degradation of PAK1 protein as glaucarubinone decreased PAK1 protein
to similar levels in the presence of a proteasomal inhibitor, MG132
(10 μM, Sigma) (Fig. 3C). Furthermore the observation that
glaucarubinone did not reduce the concentration of PAK1 mRNA
(Fig. 3D), suggested that glaucarubinone reduced PAK1 protein expres-
sion independently of any changes in PAK1 transcription. These observa-
tions suggested that the reduction by glaucarubinone of PAK1 kinase
activity was due to inhibition of PAK1 protein expression, and that the
inhibition of PAK1protein by glaucarubinonewasneither via suppression
of PAK1 mRNA, nor through promotion of protein degradation.
To determinewhether or not glaucarubinone directly inhibited PAK1,
the kinase activity of a bacterially expressedGST-PAK1 fusionproteinwas
measured in the presence of increasing concentrations of glaucarubinone
(Fig. 3E). PAK1 kinase activity was not affected by glaucarubinone at
500 nM and only decreased to 80% at 1 μM.Glaucarubinone did not affect
the kinase activities of either PAK2, or PAK4, or their protein concentra-
tions (Supplementary Fig. 1). These data conﬁrmed that glaucarubinone
inhibited PAK1 kinase activity by down-regulation of its protein
expression.. The IC50 values for glaucarubinone inhibition of CRC cell proliferation (A)were determined
ned byWestern blots, and expressed as a ratio of the GAPDH (B). To show the difference in
ich had the lowest PAK1, was taken as 1. The correlation between the glaucarubinone IC50
the program Sigmaplot 12. PAK1 knockdown clones (IS3.4 and IS3.6) and negative control
e. Constitutively active PAK1 clones (CA13 and CA16) and a vector only-transfected clone
. The IC50 values for inhibition by glaucarubinone were calculated using data from three
.
Fig. 3.Glaucarubinone inhibited PAK1 activity by down-regulation of PAK1 expression. CRC cellswere culturedwith orwithout glaucarubinone (Glau, 100 nMor 500nM) for 24 h (A, B, D), in
thepresenceor absence of the proteasomal inhibitorMG132 (10 μg/ml, C), and lysed. The cell lysateswere immunoprecipitatedwith anti-PAK1 antibody, and the in vitro kinase activity of the
immunoprecipitates was assayed by phosphorylation of myelin basic protein (MBP) as described in theMaterial andmethods section (A). The expression of phosphorylated PAK1 (pPAK1,
B) and total PAK1 (C)was determined byWestern blot, and the ratios of pPAK1 (B) or total PAK1 (C) to GAPDH in control cells were taken as 1. The amount of PAK1mRNA and 18S RNAwas
determined by real time PCR, and the ratio of PAK1mRNA to 18SmRNA in each untreated cell linewas taken as 1 (D). The kinase activity of a bacterially expressed GST-PAK1 fusion protein
was measured by phosphorylation of myelin basic protein (MBP) in the presence of glaucarubinone (0.1–1 μM) or the speciﬁc PAK1 inhibitor frax 597 (10 nM) (E). The data were summa-
rized from three independent experiments and presented as mean ± standard error. Cont: control, pMBP: phosphorylated myelin basic protein (MBP), tMBP: total MBP, *, p b 0.05; **,
p b 0.01; ***, p b 0.001 compared to control.
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of PAK1
Both HIF-1α and β-catenin play key roles in CRC progression. To
determine the effect of glaucarubinone on HIF-1α and β-catenin,
the levels of these proteins in CRC cells incubated with or without
glaucarubinone were measured by Western blot. Glaucarubinone
inhibited the expression of both HIF-1α (Fig. 4A) and β-catenin
(Fig. 4B) in DLD1, HCT116 and SW480 cells, but not in HT29 cells
which had a signiﬁcantly higher level of PAK1. To determine whether
the effect of glaucarubinone was speciﬁc to HIF-1α and β-catenin, the
levels of total and phosphorylated ERK and total and phosphorylated
AKT in the same CRC cell extracts were measured by Western blot.
Glaucarubinone did not reduce the levels of total and phosphorylated
ERK – or AKT (Fig. 4C). These data suggested that glaucarubinone
inhibited CRC cell growth by suppression of HIF-1α and β-catenin.
Todetermine the role of PAK1 in the suppressionbyglaucarubinone of
HIF-1α andβ-catenin expression in CRC cells, both PAK1 KDHCT116 cells
and SW480 cells over-expressing constitutively active (CA) PAK1 were
treated with glaucarubinone, and the levels of HIF-1α and β-catenin
were measured by Western blot. Over-expression of CA PAK1 reversed
the inhibition by glaucarubinone of HIF-1α and β-catenin expression
(Fig. 5A & B). On the other hand, the inhibition by glaucarubinone of
HIF-1α and β-catenin expression was signiﬁcantly enhanced in PAK1
knockdown cells (Fig. 5C & D). Glaucarubinone decreased the amount of
endogenous PAK1 in vector only transfected cells, but not in CA PAK1
transfected cells (Fig. 5E, top panel). However glaucarubinone reducedFig. 4.Glaucarubinone suppressed the expression ofHIF-1α andβ-catenin, but not of active and
(Glau) for 24 h. The expression of HIF-1α (A), β-catenin (B), phosphorylated ERK (pERK), total
The expression ratios relative to GAPDH in the control sampleswere taken as 1. The datawere su
*, p b 0.05; **, p b 0.01; ***, p b 0.001 compared to control.the amount of PAK1 not only in negative control (NC) cells but also in
PAK1 KD cells (Fig. 5E, bottom panel). These results indicated that
PAK1 mediated the inhibitory effect of glaucarubinone on HIF-1α and
β-catenin in CRC cells.3.5. Glaucarubinone inhibited CRC growth in vivo by suppression of PAK1,
HIF-1α and β-catenin
The effect of glaucarubinone on CRC cell growth in vivowasmeasured
in a mouse xenograft model as described in the Material and methods
section. The xenograft growth of HCT116 cells was decreased by
glaucarubinone treatment as the tumor volumewas reduced signiﬁcantly
fromday 6 of glaucarubinone treatment onwards (Fig. 6A). No signiﬁcant
toxicity was observed under the experimental conditions as the body
weights of the mice treated with glaucarubinone were not signiﬁcantly
different compared to the control group (Fig. 6B). Similar results were
obtained for the xenograft growth of DLD1 cells (Supplementary Fig. 2).
To investigate the mechanisms involved, proteins were extracted
from the tumors of control and glaucarubinone-treated mice at the
end of the experiment, and the levels of proteins were determined by
Western blot. As with the in vitro results, glaucarubinone inhibited the
expression of HIF-1α, β-catenin, and both total and active PAK1
(Fig. 6C), but had no effect on the expression of either ERK or AKT.
These results indicated that glaucarubinone suppressed the in vivo
growth of CRC cells by down-regulation of HIF-1α and β-catenin,
possibly via a PAK1-dependent pathway.total ERKandAKT. CRC cellswere incubatedwith 0 [16], 100 nMor 500 nMglaucarubinone
ERK (C), phosphorylated AKT (pAKT), and total AKT (C) was determined byWestern blot.
mmarized from three independent experiments and presented asmean± standard error.
Fig. 5. Inhibition ofHIF-1α andβ-cateninby glaucarubinonewas reversed in CA-PAK1cells, but enhanced inPAK1KDcells. Constitutively active PAK1 clones CA13 andCA16 anda vector only
clone (VO1) of SW480 cells (A, B), and PAK1 knockdown clones IS3.4, IS3.6 and a negative control clone (NC8) of HCT116 cells (C, D), were cultured with 0 [16] or 100 nM glaucarubinone
(Glau). The expression of HIF-1α (A, C) andβ-catenin (B, D)wasmeasured byWestern blot. The expression ratios relative to GAPDH in the control samples of VO1 or NC8 cellswere taken as
1. The amounts of PAK1 and PAK1 CA with or without glaucarubinone treatment are presented in E. The data were summarized from four independent experiments and are presented as
mean ± standard error. *, p b 0.05; **, p b 0.01; control vs glaucarubinone-treatment. ##, p b 0.01 compared to control VO1 or control NC8; ^, p b 0.05, ^^, p b 0.01 compared to
glaucarubinone-treated VO1 or NC8.
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We report here that glaucarubinone inhibits CRC growth in vitro and
in vivo. The inhibition by glaucarubinone of CRC cell proliferation corre-
lated with PAK1 expression as lower PAK1 expression rendered CRC
cells more sensitive to glaucarubinone (Fig. 2). Furthermore, the inhibi-
tory effect of glaucarubinone on CRC cell proliferation was enhanced by
inhibition of PAK1 by knocking down PAK1, and decreased by increasing
PAK1 activity via expression of constitutively active (CA) PAK1 in CRC
cells. In fact, glaucarubinone suppressed PAK1 activity by reducing its
protein expression in CRC cells (Fig. 3). These observation are consistent
with our recent publication that glaucarubinone and gemcitabine syner-
gistically inhibited pancreatic cancer growth by down-regulation ofPAK1 [26]. Although the suppression of PAK1 activity by glaucarubinone
in cells is unlikely to be due to a direct inhibition by glaucarubinone of
the kinase activity of PAK1 (Fig. 3), it is possible that glaucarubinone
may decrease PAK1 activity by reducing PAK1 protein expression via
suppression of a post-transcriptional pathway. The mechanism involved
in down-regulation of PAK1 protein expression and suppression of PAK1
activity by glaucarubinone in cells needs further investigation. Although
the inhibitory effect of glaucarubinone on cell proliferation correlated
with levels of PAK1 protein in CRC cells, the effect of glaucarubinone
may not be mediated entirely by PAK1.
The inhibition by glaucarubinone of CRC growth was also associated
with decreased expression of HIF-1α and β-catenin in both CRC cells
(Fig. 4) and xenografted tumors (Fig. 6) under glaucarubinone treatment.
Fig. 6.Glaucarubinone inhibited the xenograft growth of CRC cells by down-regulation of PAK1, HIF-1α andβ-catenin. HCT116 cellswere subcutaneously injected into theﬂanks of 10 SCID
mice, whichwere then divided into control (Cont, n= 5) and glaucarubinone-treated (Glau, n= 5) groups. The controlmicewere injected intra-peritoneally with 5%DMSO in saline and
the glaucarubinone-treatedmicewith 1 mg/kg glaucarubinonedissolved in 5%DMSO in saline for 3 weeks as described in theMaterial andmethods section. The tumor volumes (A), body
weights (B) and protein concentrations (C) were measured with a caliper, by weighing and by Western blot, respectively, as described in the Material and methods section. The protein
concentrations were expressed as ratios relative to the GAPDH in each sample. *, p b 0.05; **, p b 0.01; ***, p b 0.001 compared to control.
164 N. Huynh et al. / Biochimica et Biophysica Acta 1853 (2015) 157–165The inhibition by glaucarubinone of HIF-1α and β-catenin expression is
not simply due to its suppression of protein synthesis as neither pERK
and ERK, nor pAKT and AKT, were affected by glaucarubinone treatment.
Furthermore the inhibition of HIF-1α and β-catenin expression by
glaucarubinone was mediated by a PAK1-dependent pathway as the
inhibitory effect was enhanced in PAK1 knockdown CRC cells but
reduced in CRC cells with over-expression of constitutively active (CA)
PAK1 (Fig. 5). Likewise glaucarubinone inhibited HIF-1α and β-catenin
expression in xenografted CRC tumors, and the inhibitionwas associated
with reduced activation of PAK1 (Fig. 6). Although the decrease in total
amount of PAK1 caused by glaucarubinone in vivodid not reach statistical
signiﬁcance, the amount of phosphorylated and active PAK1 was signiﬁ-
cantly reduced by glaucarubinone. Together these data suggested that
glaucarubinone inhibited CRC growth by down-regulation of HIF-1α
and β-catenin via a PAK1-dependent pathway.
These observations are consistent with previous reports of connec-
tions between PAK1 and β-catenin signaling. PAK1 phosphorylates β-
catenin and stimulates β-catenin nuclear translocation and activation
in CRC cells [16,17]. PAK1 also stimulates CRC growth and metastasis
by activation of β-catenin [16]. We have previously reported that PAK1
correlates closely with HIF-1α and β-catenin in intestinal and colorectal
cancers in the APCΔ14 mice model [18]. Inhibition of PAK1 expression by
small interfering RNA reduced the expression of both β-catenin and HIF-
1α, and the reduction was associated either with a decreased tumor
number in APCΔ14 mice, or with reduced tumor survival in a CRC xeno-
graft model [18]. Conversely PAK1 promoted hypoxia-induced HIF-1α
expression leading to increased survival of CRC cells [18]. These ﬁndings
demonstrate that PAK1 is a key regulator of HIF-1α andβ-catenin in CRC
growth and survival. In the present study, we show that PAK1 mediated
the inhibitory effects of glaucarubinone onHIF-1α andβ-catenin expres-
sion, which in turn led to inhibition of CRC growth.
Members of the quassinoid family, including glaucarubinone, have
been found to affect multiple cellular processes, such as inhibition of
proliferation, suppression of DNA and protein synthesis, and induction
of apoptosis [19]. Quassinoids act through targeting multiple signaling
pathways. For example, NBT-272 induced cell cycle arrest and inhibitedproliferation by down-regulation ofmyc, an oncogenewhich is frequent-
ly over-expressed in various tumors [31]. 6α-tigloxychaparrinone, anoth-
er quassinoid, decreased hypoxia-inducedHIF-1αprotein expression and
mRNA translation in gastric cancer cells through an ERK-dependent path-
way [25]. For the ﬁrst time, we report here that glaucarubinone inhibited
the protein expression of both HIF-1α and β-catenin in CRC cells by
modulation of PAK1 activity, leading to decreased CRC growth. HIF-1α
and β-catenin play important roles in CRC growth and metastasis. PAK1
has recently been identiﬁed as a point of convergencemediatingmultiple
signals important for cancer progression [32]. PAK1 promotes CRC
growth and metastasis by activation of β-catenin [16,17], and enhances
CRC survival through up-regulation of HIF-1α [18]. The connection
from glaucarubinone to PAK1, HIF-1α and β-catenin provides signiﬁcant
insight into the mechanism involved in the anticancer function of
quassinoids. Given this mode of action, quassinoids would seem to
be worthy of further study as a CRC treatment. However the fact
that CRC cell lines with lower PAK1 expression are more sensitive
to glaucarubinone implies that glaucarubinone may be more effective
in chemoprevention or adjunct chemotherapy after tumor resection.
In summary we have demonstrated in this paper that glaucarubinone
inhibited CRC cell growth in vitro and in vivo by down-regulation of HIF-
1α and β-catenin expression via a PAK1-dependent pathway. These
ﬁndings further conﬁrm the central role of PAK1 in CRC progression and
provide insight into the mechanism involved in the anticancer activity
of glaucarubinone.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.10.013.
Funding
This work was supported by the National Health and Medical
Research Council (NHMRC) of Australia grants 508908 (HH) and
1041831 (GB & AS), by the Austin Hospital Medical Research Founda-
tion 2-1281 (HH), and by the Intramural Research Program of the NIH
National Cancer Institute Center for Cancer Research 1 ZIA BC011470
02 (JB).
165N. Huynh et al. / Biochimica et Biophysica Acta 1853 (2015) 157–165Acknowledgements
We thank theDrug Synthesis & Chemistry Branch, NCI, for supplying
the glaucarubinone and ailanthinone used in this study, and Hiroshi
Maruta for his stimulating discussions.
References
[1] R. Fodde, R. Smits, H. Clevers, APC, signal transduction and genetic instability in
colorectal cancer, Nat. Rev. Cancer 1 (2001) 55–67.
[2] S.M. Powell, N. Zilz, Y. Beazer-Barclay, et al., APC mutations occur early during
colorectal tumorigenesis, Nature 359 (1992) 235–237.
[3] M. Hockel, P. Vaupel, Tumor hypoxia: deﬁnitions and current clinical, biologic, and
molecular aspects, J. Natl. Cancer Inst. 93 (2001) 266–276.
[4] T. Isobe, K. Aoyagi, K. Koufuji, et al., Clinicopathological signiﬁcance of hypoxia-
inducible factor-1 alpha (HIF-1alpha) expression in gastric cancer, Int. J. Clin.
Oncol. 18 (2013) 293–304.
[5] Y. Baba, K. Nosho, K. Shima, et al., HIF1Aoverexpression is associatedwith poor prog-
nosis in a cohort of 731 colorectal cancers, Am. J. Pathol. 176 (2010) 2292–2301.
[6] G.L. Semenza, Hypoxia-inducible factors in physiology and medicine, Cell 148
(2012) 399–408.
[7] A. Kaidi, A.C. Williams, C. Paraskeva, Interaction between beta-catenin and HIF-1
promotes cellular adaptation to hypoxia, Nat. Cell Biol. 9 (2007) 210–217.
[8] J.L. Martindale, N.J. Holbrook, Cellular response to oxidative stress: signaling for
suicide and survival, J. Cell. Physiol. 192 (2002) 1–15.
[9] D.A. Patten, V.N. Laﬂeur, G.A. Robitaille, et al., Hypoxia-inducible factor-1 activation
in nonhypoxic conditions: the essential role of mitochondrial-derived reactive
oxygen species, Mol. Biol. Cell 21 (2010) 3247–3257.
[10] D.T. Dang, F. Chen, L.B. Gardner, et al., Hypoxia-inducible factor-1alpha promotes
nonhypoxia-mediated proliferation in colon cancer cells and xenografts, Cancer
Res. 66 (2006) 1684–1936.
[11] S.M. Welford, B. Bedogni, K. Gradin, et al., HIF1alpha delays premature senescence
through the activation of MIF, Genes Dev. 20 (2006) 3366–3371.
[12] P.R. Molli, D.Q. Li, B.W. Murray, et al., PAK signaling in oncogenesis, Oncogene 28
(2009) 2545–2555.
[13] R. Kumar, A.E. Gururaj, C.J. Barnes, p21-Activated kinases in cancer, Nat. Rev. Cancer
6 (2006) 459–471.
[14] J.H. Carter, L.E. Douglass, J.A. Deddens, et al., Pak-1 expression increaseswith progres-
sion of colorectal carcinomas to metastasis, Clin. Cancer Res. 10 (2004) 3448–3456.
[15] N. Huynh, K.H. Liu, G.S. Baldwin, et al., P21-activated kinase 1 stimulates colon cancer
cell growth and migration/invasion via ERK- and AKT-dependent pathways,
Biochim. Biophys. Acta 1803 (2010) 1106–1113.[16] H. He, N. Huynh, K.H. Liu, et al., P-21 activated kinase 1 knockdown inhibits beta-
catenin signalling and blocks colorectal cancer growth, Cancer Lett. 317 (2012)
65–71.
[17] G. Zhu, Y. Wang, B. Huang, et al., A Rac1/PAK1 cascade controls beta-catenin activa-
tion in colon cancer cells, Oncogene 31 (2012) 1001–1012.
[18] K.H. Liu, N. Huynh, O. Patel, et al., P21-activated kinase 1 promotes colorectal cancer
survival by up-regulation of hypoxia-inducible factor-1alpha, Cancer Lett. 340
(2013) 22–29.
[19] G. Fiaschetti, M.A. Grotzer, T. Shalaby, et al., Quassinoids: from traditional drugs to
new cancer therapeutics, Curr. Med. Chem. 18 (2011) 316–328.
[20] Z. Guo, S. Vangapandu, R.W. Sindelar, et al., Biologically active quassinoids and their
chemistry: potential leads for drug design, Curr. Med. Chem. 12 (2005) 173–190.
[21] J.A. Beutler, M.I. Kang, F. Robert, et al., Quassinoid inhibition of AP-1 function does not
correlate with cytotoxicity or protein synthesis inhibition, J. Nat. Prod. 72 (2009)
503–506.
[22] N. Fukamiya, K.H. Lee, I. Muhammad, et al., Structure–activity relationships of
quassinoids for eukaryotic protein synthesis, Cancer Lett. 220 (2005) 37–48.
[23] M. Cuendet, K. Christov, D.D. Lantvit, et al., Multiple myeloma regression mediated
by bruceantin, Clin. Cancer Res. 10 (2004) 1170–1179.
[24] M. Cuendet, J.J. Gills, J.M. Pezzuto, Brusatol-induced HL-60 cell differentiation involves
NF-kappaB activation, Cancer Lett. 206 (2004) 43–50.
[25] X. Jin, H.R. Jin, D. Lee, et al., A quassinoid 6alpha-tigloyloxychaparrinone inhibits
hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation
factor 4E phosphorylation, Eur. J. Pharmacol. 592 (2008) 41–47.
[26] D.H.N. Yeo, J.A. Beutler, C. Christophi, A. Shulkes, G.S. Baldwin, M. Nicfarjam, H. He,
Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth
via down-regulation of P21-activated kinases, Cancer Lett. 346 (2014) 264–272.
[27] D. Mouradov, C. Sloggett, R.N. Jorissen, et al., Colorectal cancer cell lines are
representative models of the main molecular subtypes of primary cancer, Cancer
Res. 74 (2014) 3238–3247.
[28] H. He, A. Levitzki, H.J. Zhu, et al., Platelet-derived growth factor requires epidermal
growth factor receptor to activate p21-activated kinase family kinases, J. Biol.
Chem. 276 (2001) 26741–26744.
[29] H. He, T. Watanabe, X. Zhan, et al., Role of phosphatidylinositol 4,5-bisphosphate in
Ras/Rac-induced disruption of the cortactin–actomyosin II complex and malignant
transformation, Mol. Cell. Biol. 18 (1998) 3829–3837.
[30] F.A. Valeriote, T.H. Corbett, P.A. Grieco, et al., Anticancer activity of glaucarubinone
analogues, Oncol. Res. 10 (1998) 201–208.
[31] A.O. von Bueren, T. Shalaby, J. Rajtarova, et al., Anti-proliferative activity of the
quassinoid NBT-272 in childhood medulloblastoma cells, BMC Cancer 7 (2007) 19.
[32] M. Radu, G. Semenova, R. Kosoff, et al., PAK signalling during the development and
progression of cancer, Nat. Rev. Cancer 14 (2014) 13–25.
